Please assess the completion status of the following clinical trial:

Trial Title: A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key inclusion criteria~* Participants willing and able to give signed and written informed consent~* Males and females, aged 18 to 89 years, who have type 2 diabetes with inadequate glycemic control (hemoglobin A1c between 7% and 10.5%) and uncontrolled hypertension (seated systolic blood pressure of 140 to 165 mm Hg and seated diastolic blood pressure 85 to 105 mm Hg)~* Mean 24-hour BP\>=130/80 mmHg determined by ABPM~* Stable dose of oral antidiabetic agent (OAD) for at least 6 weeks (12 weeks for thiazolidinedione) or a stable daily dose of insulin as monotherapy or in combination with another OAD, for 8 weeks, and a stable dose of an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker for at least 4 weeks~* C-peptide level ≥0.8 ng/mL~* Body mass index ≤ 45.0 kg/m\^2~Key exclusion criteria~* Aspartate aminotransferase or alanine aminotransferase level \>3\*upper limit of normal (ULN)~* Serum total bilirubin level \>1.5\*ULN~* Serum creatinine ≥2.0 mg/dL unless subject was on metformin, where exclusionary limits were serum creatinine ≥1.50 mg/dL for men and ≥1.40 mg/dL for women~* Estimated creatinine clearance of \<60 mL/min~* Hemoglobin ≤10.0 g/dL for men and ≤9.0 g/dL for women~* Creatine kinase \>3\*ULN~* Positive for hepatitis B surface antigen~* Positive for antihepatitis C virus antibody~* Abnormal free T4 value~* History of diabetes insipidus~* Symptoms of poorly controlled diabetes that would preclude participation in this trial, including but not limited to, marked polyuria and polydipsia with greater than 10% weight loss during the 3 months prior to enrollment.~* History of diabetic ketoacidosis or hyperosmolar nonketotic coma~* History of malignant and accelerated hypertension~* Known or suspected secondary hypertension~* Any of the following within 6 months of enrollment visit:~  * Myocardial infarction~ * Cardiac surgery or revascularization (coronary artery bypass surgery /percutaneous transluminal coronary angioplasty)~ * Unstable angina~ * Unstable congestive heart disease or New York Heart Association Class III or IV~ * Transient ischemic attack or significant cerebrovascular disease~ * Unstable or previously undiagnosed arrhythmia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin, 10 mg (Type: EXPERIMENTAL): Oral tablets administered as 10 mg once daily for up to 12 weeks
- Placebo-matching dapagliflozin (Type: PLACEBO_COMPARATOR): Oral tablets administered once daily in the morning
- Dapagliflozin, 2. 5 mg (Type: EXPERIMENTAL): Oral tablets administered as 2.5 mg once daily for up to 12 weeks (Arm discontinued as of Protocol Amendment 8)
- Dapagliflozin, 5 mg (Type: EXPERIMENTAL): Oral tablets administered as 5 mg once daily for up to 12 weeks (Arm discontinued as of Protocol Amendment 8)

Based on this trial design, predict the completion outcome and termination type (if applicable).